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Abstract
Background: To compare computed tomography (CT) with co-registered positron emission
tomography-computed tomography (PET-CT) as the basis for delineating gross tumor volume
(GTV) in unresectable, locally advanced pancreatic carcinoma (LAPC).
Methods: Fourteen patients with unresectable LAPC had both CT and PET images acquired. For
each patient, two three-dimensional conformal plans were made using the CT and PET-CT fusion
data sets. We analyzed differences in treatment plans and doses of radiation to primary tumors and
critical organs.
Results: Changes in GTV delineation were necessary in 5 patients based on PET-CT information.
In these patients, the average increase in GTV was 29.7%, due to the incorporation of additional
lymph node metastases and extension of the primary tumor beyond that defined by CT. For all
patients, the GTVCT versus GTVPET-CT was 92.5 ± 32.3 cm3 versus 104.5 ± 32.6 cm3 (p = 0.009).
Toxicity analysis revealed no clinically significant differences between two plans with regard to
doses to critical organs.
Conclusion: Co-registration of PET and CT information in unresectable LAPC may improve the
delineation of GTV and theoretically reduce the likelihood of geographic misses.
Background
Surgery offers the only potential cure for pancreatic carci-
noma; however, more than 85% of patients have tumors
that are not amenable to surgical resection, due to
advanced disease at presentation [1,2]. Although 45% of
those patients present with metastatic disease, the remain-
ing 40% present with unresectable, locally advanced pan-
creatic carcinoma (LAPC). These patients still have a
theoretical chance for cure with non-surgical treatment,
such as systemic chemotherapy and/or radiation therapy
(RT) [2,3]. However, in unresectable LAPC, reported local
relapse rates after RT are high, ranging from 42% to 68%
[4,5]; these rates may be associated with either geographic
misses or the insufficiency of conventional radiation
doses of 45–50 Gy.
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An obvious way to reduce geographic misses in pancreatic
carcinoma is through a more accurate definition of RT tar-
get volumes. However, contrast-enhanced computerized
tomography (CT), which is the current standard imaging
modality for planning three-dimensional conformal RT
(3D-CRT), has a relatively low sensitivity and specificity in
determining the extent of primary tumor and nodal
involvement [6-13], which directly impact the definition
of target volumes. Therefore, it is desirable to supplement
CT when defining gross tumor volume (GTV) and its sub-
sequent expansion to planning target volume (PTV).
In several tumor sites including pancreas, functional 18F-
fluoro-deoxyglucose positron emission tomography
(FDG-PET) has been shown to have higher sensitivity and
specificity than anatomic CT in the detection of primary
tumors, lymphatic extensions, and distant metastases [14-
18]. Potential roles of FDG-PET in imaging pancreatic car-
cinoma have been demonstrated [8-10,12,19], but the
precise delineation of positive findings is hampered by
limited anatomic information provided by PET images
[20,21]. However, this limitation may be overcome by
using co-registered functional PET and anatomic CT
images, which may further improve delineation of target
volumes by providing better discrimination between
malignant and benign lesions and determining lymphatic
status. PET-CT based RT planning (RTP) has been shown
to significantly alter RT fields in patients with various
tumors, such as cancers of the head and neck, lung, and
esophagus [22-24]. However, to our knowledge, there is
no report on the role of PET-CT based RTP in patients with
unresectable LAPC. We hypothesized that using PET-CT
data rather than CT data alone would change RT fields and
possibly result in fewer geographic misses for pancreatic
region. In this current study, we compared CT- and PET-
CT-based GTV delineation and its subsequent expansion
to the PTV; we also analyzed the resultant doses of 3D-
CRT to critical organs.
Methods
Patient population
Fourteen patients with pathologically confirmed, unre-
sectable LAPC were prospectively enrolled. Other eligibil-
ity criteria were as follows: Eastern Cooperative Oncology
Group performance status (PS) of 0 to 2; age between 18
and 70 years; determination of disease extent by laparot-
omy or laparoscopy, and radiographic imaging; no prior
chemotherapy or abdominal irradiation; no contraindica-
tion for PET-CT imaging. All patients provided written
informed consent, and the study design was approved by
the institutional ethics committee, in accordance with
Helsinki Declaration on human projects.
CT and PET imaging
Prior to the CT and PET imaging, patients were immobi-
lized in customized alpha cradles in the simulation posi-
tion, which is supine with arms up. Before imaging,
simulator lasers (Acuity, Varian Medical Systems, Palo
Alto, CA, USA) were used to align and mark patients to
define the coordinate system that would be used for treat-
ment planning.
For PET-based planning, eligible patients were investi-
gated with the combined PET-CT system (Discovery-STE
8, General Electric Medical System, Milwaukee, WI, USA).
The patients fasted for at least 6 hours before administra-
tion of intravenous 370–555 MBq (10–15 mCi) FDG. Pre-
injection blood glucose levels were measured to ensure
that they were below 150 mg/dl. During the distribution
phase the patients lay supine in a quiet room. The com-
bined image acquisition started 60 minutes after the FDG
injection. The patients were scanned on the flat-panel car-
bon fiber composite table insert. At first, an unenhanced
CT scan (5 mm slice thickness) from the base of the skull
to the inferior border of the pelvis was acquired, using a
standardized protocol with 140 kV, 80 mA. The subse-
quent PET scan was acquired in 3D mode from the base of
the skull to the inferior border of the pelvis (6–7 bed posi-
tions, 3 min per bed position) without repositioning the
patient on the table. Both CT and PET images were
acquired with the patient breathing shallowly. Attenua-
tion was corrected by using the CT images. Areas of FDG
uptake were categorized as malignant based on location,
intensity, shape, and size and visual correlation with CT
images to differentiate physiologic from pathologic
uptake.
Image registration and radiation treatment planning
Eclipse 7.5 (Varian Medical Systems, Palo Alto, CA, USA)
RTP system, which includes all standard RTP features as
well as DICOM image read and the automated image reg-
istration software, was used to perform CT- and PET-CT-
based treatment planning for each patient. Two radiation
oncologist contoured the GTV, the PTV, and the normal
organs of interest on the CT images, independent of the
PET images. For purposes of this study, a nuclear medicine
physician outlined the lesion on the registered PET
images. We set the window and level for the PET images
according to the method previously described by Erdi et
al. [25] for accurate target volume definition. In this pro-
tocol, we first measured the value of the hottest pixel in
the lesion and then set the upper window level to this
maximum value and lower window level to 42% of the
maximum level.
The target volumes were consensually defined by two
radiation oncologists with specific experience in pancre-
atic cancer treatment. Despite of their large experience onJournal of Experimental & Clinical Cancer Research 2008, 27:41 http://www.jeccr.com/content/27/1/41
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delineating target volumes in this disease site, we
addressed the possible interobserver variability between
two observers in 6 sampled patients. The variability was
less than 0.4 mm for GTV and 0.5 mm for PTV delinea-
tions, respectively. For each patient, the GTVCT was con-
toured to include the visible primary tumor and involved
peripancreatic lymph nodes (≥1.5 cm in short axis). On
the other hand, GTVPET-CT contouring included the pri-
mary tumor and the lymph nodes that appeared to be
involved on either of CT (≥1.5 cm in short axis) and/or
PET images irrespective of their size. For each method, our
PTV was defined as GTV + 2 cm in each direction, to allow
for microscopic extension and patient motion. To facili-
tate the comparison of methods, the three dimensional
treatment plans and dose volume histograms (DVHs) for
CT- only and PET-CT- based data were generated sepa-
rately for each patient.
We planned to treat a single target volume with no cone
down volumes. Treatment volumes were defined by using
customized multileaf collimation. A four-field technique
(posteroanterior, anteroposterior, and laterals) was man-
dated. A dose of 50.4 Gy (1.8 Gy/fr) was prescribed to
encompass the defined PTV with isodose lines not 'cooler'
than 95% and not 'hotter' than 107%. To achieve this, we
used dosimetric practice wedges to modify beams. The
source to axis distance was 100 cm. For each method,
RTPs and DVHs were generated for 18 MV photon energy.
For normal tissues, the maximum dose limits were of 45
Gy for the spinal cord, 50 Gy for the small bowel and
stomach, 36 Gy for the liver, and 20 Gy to at least two
thirds of one functioning kidney.
Statistical analysis
On the basis of the literature concerning other tumor
types, we hypothesized that integration of PET into RTP
would change the target volumes in approximately 30%
of the patients. In order to detect such a change with a
95% confidence interval of 5–55%, we needed to enroll at
least 13 patients.
Statistical differences between paired parameters from CT-
versus PET-CT-based treatment plans were evaluated with
the Wilcoxon signed rank test. Results are either expressed
as mean ± Standard deviation (SD) or as a proportion of
95% confidence intervals (95% CI). Differences were con-
sidered significant when the two-tailed p-value was less
than 0.05.
Results
The pretreatment tumor and patient characteristics for the
14 analyzable patients are summarized in Table 1.
Although there was a need to change in both GTV and PTV
based on PET information in all of the patients, this need
was more prominent in 5 (35.7%) of them. The mean
increase in GTV and corresponding PTV were; 29.7%
(95% CI: 18.2–40.6) and 13.4% (95% CI: 8.6–21.3,) in
this patients group (Figure 1). The reasons for these
changes in GTV were detection of primary tumor beyond
the CT-defined tumor boundaries in 4 (28.5%) patients,
and detection of additional lymph node metastases in 1
(7.2%). The mean increase in GTV was 29.7% (95% CI:
18.2–40.6) in this patients group. Compared to CT-based
delineation, the PET-CT-based delineation resulted in a
significant increase in both the mean GTVs and the mean
PTVs in the whole study population (Table 2).
An overview of the radiation exposure of normal tissues,
comparing CT- and PET-based plans, is shown in Table 2.
Based on the DVHs for the two RTPs, there was no clini-
cally significant difference in the percentage of the PTV
dose that was received by critical organs other than the
right kidney. However, for the right kidney, the PET-based
delineation of the target volumes resulted in a mean
increase in radiation exposure by 5.3%.
Discussion
We compared CT- and PET-CT-based target volume delin-
eation for unresectable LAPC and the effects of these dif-
ferent modalities on 3-D-CRT planning and radiation
doses to critical organs. Our results demonstrated that
Representative image of a patient with different GTV delineations; CT (A), PET (B), and co-registered PET-CT Figure 1
Representative image of a patient with different GTV delineations; CT (A), PET (B), and co-registered PET-
CT.Journal of Experimental & Clinical Cancer Research 2008, 27:41 http://www.jeccr.com/content/27/1/41
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PET-CT-based target volume contouring significantly
increases the GTV and the PTV compared to CT-based con-
touring without increasing tissue toxicity in a clinically
meaningful way.
The current treatment of choice for patients with unresect-
able LAPC consists of concurrent or sequential chemo-
radiotherapy. In spite of significant improvements in
chemotherapy and radiation oncology, the observed rates
of local control remain far from acceptable limits. A theo-
retically reasonable way to reduce local recurrence is the
accurate definition of target volumes and administration
of appropriate radiation doses to these volumes. How-
ever, the accurate definition and contouring of the bound-
aries of the primary tumor and its locoregional extension
are difficult with conventional imaging modalities, and a
significant inter-observer variation has been demon-
strated. Compared to non-registered images the co-regis-
tration of CT and PET images reduces inter-observer
variability for different tumor types [26-28], and offers a
higher sensitivity and accuracy in delineating primary
tumors and lymph node metastases [14,29]. In a series of
52 patients with pancreatic carcinoma, Delbeke et al. [30]
demonstrated that FDG-PET had a higher sensitivity, spe-
cificity and accuracy than CT in diagnosing pancreatic car-
cinoma (92%, 85% and 91% for FDG-PET versus 65%,
61% and 65% for CT, respectively). In another study,
Lemke et al (31) compared the diagnostic value of CT,
PET, and PET-CT fusion in 104 patients with susceptible
pancreatic lesions. The authors reported that the image
fusion improved the sensitivity of malignancy detection
from 76.6% (CT) and 84.4% (PET) to 89.1% (image
fusion). Compared to CT alone, image fusion increased
the sensitivity of detecting infiltration of adjacent tissue
from 47.7% to 68.2%. Based on the above literature, we
hypothesized that the accuracy of target volume delinea-
tion might be improved beyond the CT-based delineation
by integrating PET and CT data. This integration provides
anatomical and functional information that may posi-
tively alter the treatment of patients with LAPC undergo-
ing 3D-CRT.
In RTP studies of various tumors, both an increase and
decrease in GTV have been observed by adding PET infor-
Table 1: Pretreatment tumor and patient characteristics
Patient Gender Age (year) Performance (ECOG) Pancreatic Primary Clinical TN-stage SUVmax
1 Male 63 2 Head T4N0 9.8
2 Male 61 1 Head T4N1 10.9
3 Male 54 1 Head T4N1 11.3
4F e m a l e 6 5 1 B o d y T 4N1 19.2
5 Male 48 0 Head T4N0 14.7
6M a l e 5 2 0 B o d y T 4N1 8.8
7F e m a l e 5 9 2 H e a d T 4N0 7.9
8 Male 57 1 Head T4N1 10.4
9 Male 46 1 Head T4N1 17.6
10 Male 51 0 Head T4N0 15.3
11 Male 58 0 Body T4N1 8.6
12 Female 62 1 Head T4N1 9.3
13 Male 43 1 Body T4N0 11.5
14 Male 55 2 Head T4N1 15.8
Abbreviations: ECOG = Eastern Cooperative Oncology Group; SUVmax = Maximum standard uptake value
Table 2: Treatment results
Parameters CT PET-CT P
GTV (cm3)
Mean ± S.D. 92.5 ± 32.3 104.5 ± 32.6 0.009
Min-max 50.0–161.2 57.8–167.4
PTV (cm3)
Mean ± S.D. 479.4 ± 103.4 535.2 ± 96.2 0.008
Min-max 337.4–708.4 376.5–728.2
Spinal cord dose (%)
Mean ± S.D. 22.8 ± 5.7 23.0 ± 5.3 0.22
Min-max 13.1–31.6 15.9–32.2
Liver dose (%)
Mean ± S.D. 36.4 ± 7.3 37.3 ± 7.5 0.17
Min-max 26.1–50,1 27.1–50.8
Stomach dose (%)
Mean ± S.D. 42.3 ± 11. 7 46.3 ± 14.5 0.08
Min-max 19.7–59.1 24.4–66.8
Left kidney dose (%)
Mean ± S.D. 23.0 ± 5.0 23.9 ± 5.1 0.12
Min-max 14.2–33.5 15.9–31.3
Right kidney dose (%)
Mean ± S.D. 44.9 ± 8.7 50.2 ± 11.2 0.03
Min-max 30.8–62.8 28.7–66.2
Abbreviations: PTV = Planning target volume; GTV = Gross tumor 
volume; S.D = Standard deviationJournal of Experimental & Clinical Cancer Research 2008, 27:41 http://www.jeccr.com/content/27/1/41
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mation to other imaging data [22-24]. While this research
may form the basis for using PET imaging for RTP in pan-
creatic cancers, to our knowledge, no studies have been
published specifically on the impact of PET imaging on
the treatment of LAPC. In head and neck [6-33], lung
[23,29] and gynecologic carcinomas [32,34] the increase
and decrease in GTV associated with adding PET informa-
tion have been demonstrated. The increase in GTV was
attributed to the detection of primary tumor beyond the
CT defined tumor boundaries, the detection of additional
lymph node metastases, or both; on the other hand, the
reduction in GTV was almost always associated with the
exclusion of nodal metastases. Limited information is
available concerning the role of PET in RTP for tumors of
the alimentary tract. Vrieze et al. [35] reported the increase
in GTV in 3 of 30 esophageal carcinomas, based on the
detection of additional pathologic lymph nodes using
FDG-PET rather than CT. Leong et al. [24] reported the
comparison of GTVCT and GTVPET in 10 esophageal carci-
nomas. In 90% of patients, PET positive lesions were
located outside GTVCT and in 30% outside the CT-based
PTV. Ciernik et al. [32] observed an increase in GTV in 3
of 6 (50%) of patients with rectal carcinoma, and this
increase in GTV lead to a 20% increase in PTV. In another
report, Lammering et al. [36] studied a group of 40
patients with rectal carcinoma and demonstrated a signif-
icant increase in GTV with PET information (GTVCT 95.9 ±
57.1 cm3 versus GTVPET 128.3 ± 80.4 cm3; P  < 0.001).
Although we studied a different tumor site (pancreas),
similar with other alimentary tract primaries as men-
tioned above, our current results demonstrated that co-
registered PET-CT findings resulted in an enlargement of
the GTV outline in 5 of 14 (35.7%) patients with an aver-
age increase of 29.7% in delineated volume.
Given the overall poor outcome in patients with pancre-
atic cancer, one may intuitively question the efficacy of
prophylactic irradiation of nodal groups as a standard
component of disease management. However, to our best
knowledge, this issue has never been addressed in a for-
mal or prospective fashion. The M.D. Anderson Cancer
Center (MDACC) has published the results of a phase 1
study using dose escalation of gemcitabine (350 mg/m2 to
500 mg/m2 weekly for 7 weekks) and hypofractionated RT
(30 Gy in 10 fractions [24,37]. Grade 3–4 hematological
and nonhematological toxicities were significant in all
three arms, probably as a result of the larger RT fields. As
an alternative strategy, Mc Ginn et al used reduced RT
fields (PTV = GTV + 1 cm without elective nodal irradia-
tion) in escalated doses of RT concurrent with gemcitab-
ine in 34 unresectable or incompletely resected pancreatic
carcinoma patients [38]. At the final planned dose level of
study (42 Gy in 15 fractions) dose limiting toxicity was
noted in two of six assessable patients. The authors con-
cluded that the use of reduced RT fields did not affect the
patterns of failure and the use of very conformal three-
dimensional treatment planning may have positively
altered the incidence of gastrointestinal toxicity. The PTV
definition utilized by Mc Ginn and associates is obviously
smaller than the one utilized in our current cohort. Based
on the above favorable data we planned to not irradiate
the CT and PET negative regional lymph nodes to an effort
to decrease the possible gastrointestinal toxicity. How-
ever, when compared we have greater chance for inciden-
tal irradiation of microscopically involved lymph nodes.
Furthermore, as we utilized PET data we have also
included the regional lymph nodes which appeared to be
metabolically involved on PET scan but not on CT. How-
ever, as the current study is going on, we think that it is
more appropriate to wait for its growing clinical reflec-
tions to achieve more precise conclusions.
The present results are important for two reasons. First, in
unresectable LAPC, the reported 42% to 68% local recur-
rence rate following RT even with chemotherapy is
extremely high [4,5]. Excluding the ineffectiveness of cur-
rent chemotherapeutics at this disease site, this recurrence
rate may partly be due to geographic misses or the insuffi-
ciency of conventional 45–50 Gy doses. The need for an
enlargement of the radiation field because of increased
GTV based on PET information in 35.7% of our patients
lends support for the possibility of geographic misses
when CT information is used as the sole imaging tool in
RTP. Second, regarding the doses to critical organs, the
analysis of the CT and PET-CT-based DVHs revealed no
clinically significant differences between the two RTPs in
our study. This finding suggests the possibility of escalat-
ing the dose safely beyond the conventional doses, which
may improve current rates of local control. However, such
dose escalation would require further research in a simi-
larly designed study, which is being tested in our ongoing
study.
Conclusion
This study demonstrated the usefulness of PET-CT based
target volume delineation in patients with LAPC. The larg-
est potential benefit of incorporating PET into RTP for
unresectable LAPC may be the reduction in geographic
misses associated with CT-based planning, and, as a
result, the potential reduction in local and regional treat-
ment failures. However, we believe that, before reaching
more precise conclusions more clinical studies are needed
to better define the role of PET-CT fusion in this setting.
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